Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 420

Similar articles for PubMed (Select 17896604)

1.

Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis.

Amarapurkar DN, Patel ND, Kirpalani AL.

Trop Gastroenterol. 2007 Jan-Mar;28(1):16-8.

PMID:
17896604
2.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
3.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

4.
5.

Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M, Kilani A, Kochlef A, Kharrat J, Ghorbel A.

Tunis Med. 2008 Apr;86(4):341-5.

PMID:
19476135
6.

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.

Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Viral Hepat. 2009 Aug;16(8):578-85. doi: 10.1111/j.1365-2893.2009.01116.x. Epub 2009 Jun 22.

PMID:
19552663
7.

Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.

Tomimatsu M, Aizawa Y, Chuganji Y, Ishizuka H, Fujita Y, Aizawa R, Abe H, Matsuda T, Itou Y, Nakanishi H, Ushiyama H, Higuchi T, Fujimoto T, Endou H, Iga D, Ohta K, Kuroda H.

J Gastroenterol Hepatol. 2006 Jul;21(7):1177-83.

PMID:
16824072
8.

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.

Benetti G, Borzio M, Ramella G, Bellati G, Fargion S, Colombo A, Croce G, Iamoletti C, Balzola F, Rizzetto M; GEL (Gruppo Epatologico Lombardo).

Intern Emerg Med. 2006;1(2):113-8.

PMID:
17111783
9.

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.

Sood A, Midha V, Hissar S, Kumar M, Suneetha PV, Bansal M, Sood N, Sakhuja P, Sarin SK.

J Gastroenterol Hepatol. 2008 Feb;23(2):203-7. Epub 2007 Jul 20.

PMID:
17645472
11.

[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].

Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.

Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):67-73. Czech.

PMID:
18756436
12.

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.

Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, Piscaglia F, Andreone P; Bologna Liver Transplantation Group (BLTG), Ballardini G, Bernardi M, Bianchi FB, Biselli M, Bolondi L, Cescon M, Colecchia A, D'Errico A, Del Gaudio M, Ercolani G, Grazi GL, Grigioni W, Lorenzini S, Pinna AD, Ravaioli M, Roda E, Sama C, Vivarelli M.

Aliment Pharmacol Ther. 2008 Aug 15;28(4):450-7. doi: 10.1111/j.1365-2036.2008.03761.x. Epub 2008 Jun 11.

13.

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.

Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, Esteban R, Guardia J, Ocaña I, Pahissa A.

AIDS. 2007 Feb 19;21(4):477-81.

PMID:
17301566
14.

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2009 Mar;81(3):452-8. doi: 10.1002/jmv.21400.

PMID:
19152407
15.
16.

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J.

J Hepatol. 2006 Jan;44(1):97-103. Epub 2005 Nov 7.

PMID:
16290907
17.

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.

Campistol JM, Esforzado N, Martínez J, Roselló L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M.

Nephrol Dial Transplant. 1999 Nov;14(11):2704-9.

18.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
19.

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.

Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V, Craxì A, Cacciola I, Squadrito G, Raimondo G.

J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):172-5.

PMID:
14518718
20.

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.

AIDS. 2008 Jan 2;22(1):15-21.

PMID:
18090387
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk